Loading people...
Bettina Ernst is the Vice President at Bernina BioInvest, a venture capital firm based in Zurich, Switzerland. Promoted to her current role in 2024, she oversees early-stage biotechnology and medtech investments for a fund managing over €200 million in assets. Prior to joining Bernina BioInvest, she co-founded and served as the Chief Executive Officer of Preclin Biosystems, a contract research organization, and held investment positions at Venturelab. Ernst holds a doctorate in immunology and pharmacology alongside a business administration degree from the University of St. Gallen, utilizing this technical expertise to support more than 20 portfolio companies. After recently participating in a €15 million Series A funding round for a Swiss biotech firm in early 2025, her current focus remains on identifying and funding early-stage healthcare and life sciences startups across the broader European venture ecosystem.
Bettina Ernst holds the pivotal role of Vice President at Bernina BioInvest, a distinguished firm dedicated to advancing innovation within the life sciences and biotechnology industries. In her capacity, Bettina is instrumental in shaping the investment strategy, identifying high-potential ventures, and guiding them through critical growth phases.
Bernina BioInvest, under the leadership contributions of professionals like Bettina Ernst, focuses on a broad spectrum of biotechnology investment areas. These typically include novel therapeutics, advanced diagnostics, medical devices, and digital health solutions that leverage biological insights. Bettina's expertise is particularly valuable in assessing the scientific merit, market potential, and operational viability of early-stage companies. She is known for her rigorous due diligence process, ensuring that Bernina BioInvest's capital is deployed into ventures with the strongest prospects for both scientific breakthroughs and commercial success.
While specific details of Bettina Ernst's career background are not publicly detailed, professionals in her position often possess a robust foundation in both scientific research and financial analysis. It is common for such investors to have prior experience in pharmaceutical companies, biotech startups, or venture capital firms, bringing a blend of scientific acumen and business development expertise to their roles. This dual perspective allows Bettina to deeply understand the complex challenges and opportunities inherent in biotech innovation, from preclinical development through clinical trials and market entry.
At Bernina BioInvest, Bettina Ernst plays a crucial role not only in sourcing deals but also in actively supporting portfolio companies. This support can range from strategic guidance on R&D pipelines and regulatory pathways to assistance with fundraising and team building. Her involvement helps to de-risk investments and accelerate the development of groundbreaking technologies that address unmet medical needs. While specific notable investments are not publicly disclosed, her work consistently aims to identify and back companies that are at the forefront of scientific discovery, promising significant returns for investors and meaningful impact for patients.
Bettina's commitment to the biotechnology sector reflects a broader vision of fostering innovation that can transform healthcare. Her strategic insights and dedication make her a key figure in the investment landscape for life sciences, contributing significantly to Bernina BioInvest's mission of funding the next generation of biotech leaders.
Bettina Ernst is the Vice President at Bernina BioInvest, a firm specializing in life sciences and biotechnology investments. She plays a key role in identifying and nurturing innovative companies within the sector.
Bettina Ernst, through Bernina BioInvest, invests in a range of biotechnology and life sciences areas. This includes novel therapeutics, advanced diagnostics, medical devices, and digital health solutions, often focusing on early-stage ventures.
Bettina Ernst works as the Vice President at Bernina BioInvest, an investment firm dedicated to the biotechnology and life sciences industries.
